# Oncotype DX Genomic Prostate Score

Source: https://onco.cc/drugs/oncotype-dx-gps/  
OnCo record `oncotype-dx-gps` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A 17-gene biopsy test that helps men with newly diagnosed low-risk prostate cancer decide whether to watch or treat.

## Summary

Developed by Genomic Health and sold by Exact Sciences until MDxHealth acquired the test in 2022, the Genomic Prostate Score predicts adverse pathology at prostatectomy and long-term metastasis and death, validated in surgical cohorts and in the Kaiser Permanente and Veterans Affairs populations. NCCN lists it for very-low to favourable-intermediate risk disease. In practice it is ordered when a man and his urologist are on the fence about active surveillance. As with Prolaris and Decipher, evidence that the test changes long-term outcomes rather than decisions is lacking.

## Fields

- Kind: Treatment
- Status: established
- Last checked: 2026-09-10
- Tags: test
- Brand: Oncotype DX GPS
- Modality: Gene-expression prognostic assay (17-gene Genomic Prostate Score)
- Mechanism: RT-PCR of 12 cancer genes across four pathways (androgen signalling, proliferation, cellular organisation, stromal response) and five reference genes on biopsy tissue, giving a 0-100 Genomic Prostate Score.

## Notes

- What a result means: a low GPS supports active surveillance; higher scores predict more aggressive disease at surgery.

## Sources

- MDxHealth: Oncotype DX GPS (page moved; nearest live section): https://mdxhealth.com/

## Connected records

- drugs: [Decipher Prostate](https://onco.cc/drugs/decipher-prostate/), [Prolaris](https://onco.cc/drugs/prolaris/)
- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- technologies: [Active surveillance](https://onco.cc/technologies/active-surveillance/), [RNA sequencing & expression profiling](https://onco.cc/technologies/rna-seq/)
- companies: [MDxHealth](https://onco.cc/companies/mdxhealth/)
- terms: [Active surveillance and observation](https://onco.cc/terms/active-surveillance-term/), [Gleason score / Grade Group](https://onco.cc/terms/gleason-grade-group/)

---
JSON: https://onco.cc/api/v1/entities/oncotype-dx-gps.json